GLP‐1 mimetics can reduce traditional cardiovascular disease risk factors such as obesity, whilst also exerting anti‐inflammatory and anti‐atherosclerotic effects as well as having positive direct modulatory effects on endothelial, cardiac and renal function (Garg et al., 2019). This evidence concerns the gene GCG and obesity disorder.